STLN.US Starling Oncology, Inc.
- Market cap
- USD 347M
- P/E
- -
- P/B
- 0.76x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is STLN.US undervalued?
Graham numberThe Graham number of Starling Oncology, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Starling Oncology, Inc. fundamental analysis
No fundamental analysis for Starling Oncology, Inc. yet.
Starling Oncology, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Starling Oncology, Inc.
Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance a…
Full company profileStarling Oncology, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Starling Oncology, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 252M | 324M | 393M | 503M | 638M |
| Gross Profit | 52.1M | 59.6M | 54.0M | 76.4M | 106M |
| Operating Income | -72.0M | -60.2M | -60.1M | -36.1M | -17.7M |
| EBITDA | 8.40M | -70.5M | -50.9M | -42.5M | -7.57M |
| Net Income | 152K | -83.1M | -64.7M | -60.6M | -37.4M |
| EPS | 0.00 | -1.12 | -0.85 | -0.66 | -0.04 |
| Balance Sheet | |||||
| Total Assets | 262M | 209M | 173M | 165M | 188M |
| Total Liabilities | 138M | 152M | 169M | 180M | 225M |
| Shareholders' Equity | 123M | 57.0M | 3.59M | -15.7M | -37.4M |
| Cash & Short-term Investments | 14.0M | 33.5M | 49.7M | 33.6M | 36.9M |
| Total Debt | - | - | - | 104M | 97.7M |
| Cash Flow | |||||
| Operating Cash Flow | -61.8M | -36.3M | -26.5M | -24.6M | 26.5M |
| Capital Expenditure | 5.53M | 4.57M | 3.79M | 3.20M | 4.28M |
| Free Cash Flow | -67.3M | -40.9M | -30.3M | -27.8M | 22.2M |
| Ratios | |||||
| ROE | 0.1% | -145.7% | -1,801.7% | - | - |
| ROA | 0.1% | -39.7% | -37.4% | -36.8% | -19.9% |
| Net Profit Margin | 0.1% | -25.6% | -16.4% | -12.1% | -5.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Starling Oncology, Inc. dividends
Starling Oncology, Inc. has not paid dividends in the last 4 fiscal years.
Who owns Starling Oncology, Inc.
- Insiders 9.97%
- Institutions 49.72%
- Public & others 40.31%
- Shares outstanding 102M
- Free float 97.0M
Top funds holding STLN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.40M | 2.35% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.96M | 1.92% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 838K | 0.82% | 0.00% | Aug 2026 |
| Nuveen Quant Small Cap Equity R6 | 635K | 0.62% | +1.62% | Sep 2026 |
| Fidelity Select Health Care Svcs Port | 628K | 0.62% | 0.00% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 557K | 0.55% | -0.38% | Oct 2026 |
| Fidelity Enhanced Small Cap Core ETF | 505K | 0.50% | +0.27% | Oct 2026 |
| Vanguard Russell 2000 ETF | 445K | 0.44% | +0.99% | Sep 2026 |
| Stt Strt® SPDR® S&P®HlthCrSvcsETF | 414K | 0.41% | 0.00% | Oct 2026 |
| Fidelity Extended Market Index | 414K | 0.41% | +20.83% | Sep 2026 |
| Vanguard US Momentum Factor ETF | 316K | 0.31% | +13.35% | Sep 2026 |
| iShares Micro-Cap ETF | 232K | 0.23% | 0.00% | Oct 2026 |
| Invesco Dorsey Wright SmallCap Momt ETF | 228K | 0.22% | -0.54% | Oct 2026 |
| LVIP FranklinTempletonMltFctSMIDCapEqStd | 223K | 0.22% | +908.16% | Sep 2026 |
| Vanguard Health Care ETF | 203K | 0.20% | +0.11% | Sep 2026 |
| Schwab Small Cap Index | 186K | 0.18% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 174K | 0.17% | +30.26% | Sep 2026 |
| iShares Russell 2000 Value ETF | 172K | 0.17% | 0.00% | Oct 2026 |
| CREF Total Global Stock Account R3 | 160K | 0.16% | -4.95% | Sep 2026 |
| Goldman Sachs Small Cap Eq Insghts Instl | 159K | 0.16% | 0.00% | Jul 2026 |
Top institutions holding STLN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 4.75M | 4.66% | +7.54% | Jun 2026 |
| Deerfield Management Co | 3.36M | 3.29% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.27M | 3.20% | -6.08% | Jun 2026 |
| JOSH ARNOLD INVESTMENT CONSULTANT, LLC | 2.46M | 2.42% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 1.90M | 1.86% | +8.09% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.74M | 1.70% | +28.36% | Jun 2026 |
| Wexford Capital LP | 1.71M | 1.68% | 0.00% | Jun 2026 |
| State Street Corp | 1.55M | 1.52% | +6.26% | Jun 2026 |
| Nuveen, LLC | 1.41M | 1.38% | +1,378.75% | Jun 2026 |
| CenterBook Partners LP | 1.24M | 1.22% | -20.83% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 1.22M | 1.20% | +257.18% | Jun 2026 |
| Renaissance Technologies Corp | 1.18M | 1.16% | -13.74% | Sep 2026 |
| Vanguard Portfolio Management, LLC | 1.01M | 0.99% | +16.71% | Jun 2026 |
| Citadel Advisors Llc | 894K | 0.88% | +46.99% | Jun 2026 |
| Jane Street Group LLC | 852K | 0.84% | +100.56% | Jun 2026 |
| Acadian Asset Management LLC | 762K | 0.75% | +34.44% | Sep 2026 |
| BRC Group Holdings Inc | 743K | 0.73% | -20.13% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 711K | 0.70% | +69.49% | Jun 2026 |
| Two Sigma Investments LLC | 669K | 0.66% | +117.33% | Jun 2026 |
| Northern Trust Corp | 592K | 0.58% | +5.92% | Jun 2026 |
Starling Oncology, Inc. company profile
- Company name
- Starling Oncology, Inc.
- Ticker
- STLN.US
- Exchange
- USA Stocks
- Listed since
- Nov 15, 2021
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Employees
- 641
- Fiscal year end
- December
- Address
- 18000 Studebaker Road, Cerritos, CA, United States, 90703
- Phone
- 562 735 3226
- Website
- starlingoncology.com
About Starling Oncology, Inc.
Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The company was formerly known as The Oncology Institute, Inc. and changed its name to Starling Oncology, Inc. in August 2026. Starling Oncology, Inc. was founded in 2007 and is headquartered in Cerritos, California.
Starling Oncology, Inc. management
10- Dr. Daniel Virnich FACHE, M.B.A., M.D.CEO & Executive Director · born 1979
- Mr. Robert CarterChief Financial Officer · born 1986
- Dr. Yale D. Podnos F.A.C.S., M.D., M.P.H.Chief Medical Officer · born 1972
- Mr. Austin LeeVP of Accounting & Controller
- Mr. Rakesh PandaChief Information Officer
- Ms. Minh MerchantChief Legal Officer · born 1973
- Mr. Nolan MarianoChief People Officer
- Mr. Mark Hueppelsheuser Esq.General Counsel
- Mr. Jordan McInerneyChief Development Officer
- Mr. Stephen CellaSenior Vice President of Finance